Gilead Sciences Inc (GILD)vsEverpure, Inc. (P)
GILD
Gilead Sciences Inc
$129.16
-1.35%
HEALTHCARE · Cap: $154.33B
P
Everpure, Inc.
$72.17
+2.67%
TECHNOLOGY · Cap: $24.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Gilead Sciences Inc generates 655% more annual revenue ($29.74B vs $3.94B). GILD leads profitability with a 31.0% profit margin vs 5.8%. P appears more attractively valued with a PEG of 1.53. GILD earns a higher WallStSmart Score of 68/100 (B-).
GILD
Strong Buy68
out of 100
Grade: B-
P
Buy57
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+42.5%
Fair Value
$221.22
Current Price
$129.16
$92.06 discount
Intrinsic value data unavailable for P.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 39 in profit
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 39.3%
Earnings expanding 54.8% YoY
Large-cap with strong market position
Attractively priced relative to earnings
Earnings expanding 139.7% YoY
Conservative balance sheet, low leverage
Revenue surging 20.4% year-over-year
Areas to Watch
Expensive relative to growth rate
4.4% revenue growth
Grey zone — moderate risk
Expensive relative to growth rate
Trading at 16.5x book value
5.8% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : GILD
The strongest argument for GILD centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.0% and operating margin at 39.3%.
Bull Case : P
The strongest argument for P centers on EPS Growth, Debt/Equity, Revenue Growth. Revenue growth of 20.4% demonstrates continued momentum.
Bear Case : GILD
The primary concerns for GILD are PEG Ratio, Revenue Growth, Altman Z-Score.
Bear Case : P
The primary concerns for P are PEG Ratio, Price/Book, Profit Margin. A P/E of 109.6x leaves little room for execution misses.
Key Dynamics to Monitor
GILD profiles as a value stock while P is a growth play — different risk/reward profiles.
P carries more volatility with a beta of 1.45 — expect wider price swings.
P is growing revenue faster at 20.4% — sustainability is the question.
GILD generates stronger free cash flow (2.4B), providing more financial flexibility.
Bottom Line
GILD scores higher overall (68/100 vs 57/100), backed by strong 31.0% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Gilead Sciences Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.
Everpure, Inc.
TECHNOLOGY · COMPUTER HARDWARE · USA
Pandora Media, Inc. provides music discovery platform services in the United States and internationally. The company is headquartered in Oakland, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?